Massimo Girardis

TL;DR: The GenOMICC (Genetics Of Mortality In Critical Care) genome-wide association study in 2244 critically ill Covid-19 patients from 208 UK intensive care units is reported, finding evidence in support of a causal link from low expression of IFNAR2, and high expression of TYK2, to life-threatening disease.

TL;DR: Assessment of the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment found it to be associated with a reduced risk.

TL;DR: Compared with healthy controls, COVID-19 patients’ T cell compartment displays several alterations involving naïve, central memory, effector memory and terminally differentiated cells, as well as regulatory T cells and PD1 + CD57 + exhausted T cells, and significant alterations exist also in several lineage-specifying transcription factors and chemokine receptors.

TL;DR: Targeted heart rates were achieved in all patients in the esmolol group compared with those in the control group and no clinically relevant differences between groups in other cardiopulmonary variables nor in rescue therapy requirements were found.

TL;DR: Among critically ill patients with an ICU length of stay of 72 hours or longer, a conservative protocol for oxygen therapy vs conventional therapy resulted in lower ICU mortality and preliminary findings were based on unplanned early termination of the trial.